Physician profile
Roger C Roque
NPI 1437156916
$22,335.75
in general payments reported to CMS, 2019-2025
70 companies · $3,950 in 2025
The $3,950 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $2,072 · 2021: $3,986 · 2022: $3,148 · 2023: $3,137 · 2024: $3,670 · 2025: $3,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $63.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,693.85 |
| Education | $63.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.49 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $2,064.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,458.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,408.00 | 2020-2021 | |
| Lilly USA, LLC | $1,246.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,152.53 | 2019-2025 | |
| Amgen INC. | $993.43 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $869.56 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $804.02 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Sumitomo Pharma America, INC. | $594.71 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $532.08 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $493.60 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.20 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $422.65 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.48 | 2019-2025 | Xifaxan, Trulance |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.